Skip to main content

Table 2 Comparative biodistribution data of [111In-DOTA]MG11 in SCID mice bearing double A431-CCK2R(+/−) tumors at 4 h pi, including controls and animals coinjected with gradually increasing amounts of TO and PA; TO and PA injected doses were equimolar

From: Impact of clinically tested NEP/ACE inhibitors on tumor uptake of [111In-DOTA]MG11—first estimates for clinical translation

Organs [111In-DOTA]MG11 (%ID/g tissue ± SD at 4 h pi, n ≥ 4)
Control +TO +PA
1.5 μg 15 μg 150 μg 3 μg 30 μg 300 μg
Blood 0.01 ± 0.01 0.02 ± 0.01 0.03 ± 0.02 0.02 ± 0.01 0.02 ± 0.01 0.04 ± 0.01 0.02 ± 0.01
Liver 0.11 ± 0.02 0.16 ± 0.02 0.15 ± 0.02 0.16 ± 0.01 0.13 ± 0.03 0.13 ± 0.02 0.12 ± 0.01
Heart 0.02 ± 0.01 0.03 ± 0.00 0.03 ± 0.00 0.03 ± 0.01 0.02 ± 0.01 0.04 ± 0.01 0.03 ± 0.01
Kidneys 1.30 ± 0.29 2.67 ± 0.30 2.28 ± 0.21 2.22 ± 0.19 2.11 ± 0.45 2.81 ± 1.03 1.78 ± 0.37
Stomach 1.32 ± 0.26 2.59 ± 0.40 3.38 ± 0.20 4.01 ± 0.20 2.68 ± 0.67 3.19 ± 0.12 4.56 ± 1.16
Intestines 0.83 ± 0.53 0.43 ± 0.10 0.47 ± 0.04 0.48 ± 0.02 0.40 ± 0.17 0.32 ± 0.09 0.47 ± 0.20
Spleen 0.06 ± 0.01 0.12 ± 0.02 0.10 ± 0.01 0.14 ± 0.04 0.09 ± 0.04 0.10 ± 0.02 0.07 ± 0.01
Muscle 0.02 ± 0.01 0.03 ± 0.01 0.02 ± 0.01 0.03 ± 0.02 0.03 ± 0.01 0.04 ± 0.01 0.02 ± 0.01
Lung 0.03 ± 0.01 0.05 ± 0.00 0.05 ± 0.00 0.62 ± 0.02 0.07 ± 0.05 0.07 ± 0.01 0.07 ± 0.03
Femur 0.02 ± 0.01 0.05 ± 0.00 0.06 ± 0.00 0.09 ± 0.07 0.04 ± 0.03 0.05 ± 0.01 0.06 ± 0.01
Pancreas 0.05 ± 0.02 0.14 ± 0.03 0.12 ± 0.03 0.22 ± 0.04 0.14 ± 0.07 0.17 ± 0.02 0.20 ± 0.03
Tumor (−) 0.12 ± 0.02 0.18 ± 0.03 0.13 ± 0.01 0.17 ± 0.04 0.17 ± 0.0.13 0.18 ± 0.07 0.13 ± 0.02
Tumor (+) 2.50 ± 0.92 4.98 ± 0.58 6.10 ± 1.26 7.99 ± 1.12 10.55 ± 1.77 15.41 ± 2.28 16.05 ± 2.37